Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

Inclusion Criteria

• Biopsy-confirmed mycosis fungoides in stage IB-IIIA
• Patients must have failed or have been intolerant to at least one prior systemic or topical therapy which may include topical steroids
• 18 years of age or older
• Life expectancy greater than 6 months
• Eastern Cooperative Oncology Group (ECOG) of /= 2000/uL; platelet count>/= 100,000/mm3; Absolute neutrophil count (ANC) >/= 1000
• Required wash out period for prior therapies (Note: patients with progressive disease may be treated earlier than required washout period per Investigator's decision) a) Topical therapy: 2 weeks, b) Systemic biologic, monoclonal antibody or chemotherapy: 4 weeks, c) Radiotherapy (excluding TSEBT) or phototherapy: 4 weeks, d) Other investigational therapy: 4 weeks
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Prior courses of TSEBT (Note: localized skin-directed radiotherapy is allowed if administered at least 4 weeks prior to initiation on study)
• Underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of patient to undergo treatment
• Prior malignancy (active within 5 years of screening) except completely excised non-invasive basal cell or squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix
• Pregnant or lactating
• Initiation or change in dosage of topical corticosteroids within 3 weeks of study treatment (Note: topical steroid use within 3 weeks is allowed provided the strength and use has been stable for at least 1 month; 'prescription strength' topical corticosteroids cannot be started during the study)
• Any other medical history, including laboratory results, deemed by the Investigator to be likely to interfere with patient participation in the study